NICE Upholds GlaxoSmithKline Appeal For Advanced Breast Cancer Treatment, Tyverb(R)(l
 

The National Institute for Health and Clinical Excellence (NICE) announced that, following GlaxoSmithKline's (GSK) appeal, it will reconsider the submission for Tyverb (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 GSK is pleased that NICE's appeal panel agreed that the draft negative guidance should be reviewed, providing fresh hope for up to 2,000 women in the UK who could benefit from this effective treatment on the NHS.

More...

Yea! So glad to hear they are fighting for this for our Her2 friends across the pond!

Great news for our friends in the UK:)

Its about time too. They should not have to wait so long to get decent treatment. I am from across the pond and have a sister in law fighting cancer and it is terrible the waits that she has to go thru. May this will speed things up. Jeanette

Brilliant news.
Hope Full of Beans also reads this!
Many thanks to all our sisters who signed the online petition.I'm sure the pressure has made NICE reconsider it's decision!
Well done also to the many UK breast oncologists who have also put pressure on NICE to reconsider their decision including the brilliant Dr Stephen Johnson,The Royal Marsden Hospital, Sutton,England
Ellie